On July 10, 2025, citing a drive to increase transparency, the Food and Drug Administration (“FDA”) published more than 200 complete response letters (CRLs) previously issued to companies that had submitted new drug...more
7/17/2025
/ Abbreviated New Drug Application (ANDA) ,
Biologics ,
Clinical Trials ,
Compliance ,
Disclosure Requirements ,
Drug Approvals ,
Drug Pricing ,
Enforcement Actions ,
Food and Drug Administration (FDA) ,
Investors ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Requirements ,
Transparency
The Office of Civil Rights of the Department of Health and Human Services (“OCR”) announced the resolution of three more right of access cases, bringing the total to a whopping 41 since the start of its drive to increase...more